Tag | Content |
---|---|
UniProt Accession | MTOR_HUMAN; P42345; |
Entrez ID | 2475 |
GenBank Protein ID | NM_004958.3; XM_005263438.2; |
GenBank Nucleotide ID | NP_004949.1; XP_005263495.1; |
Protein Name | Serine/threonine-protein kinase mTOR (EC 2.7.11.1) (FK506-binding protein 12-rapamycin complex-associated protein 1) (FKBP12-rapamycin complex-associated protein) (Mammalian target of rapamycin) (mTOR) (Mechanistic target of rapamycin) (Rapamycin and FKBP |
Gene Name | MTOR; FRAP; FRAP1; FRAP2; RAFT1; RAPT1 |
Organism | Homo sapiens |
NCBI Taxa ID | 9606 |
Functional Description | Serine/threonine protein kinase which is a central regulator of cellular metabolism, growth and survival in response to hormones, growth factors, nutrients, energy and stress signals. MTOR directly or indirectly regulates the phosphorylation of at least 800 proteins. Functions as part of 2 structurally and functionally distinct signaling complexes mTORC1 and mTORC2 (mTOR complex 1 and 2). Activated mTORC1 up-regulates protein synthesis by phosphorylating key regulators of mRNA translation and ribosome synthesis. This includes phosphorylation of(view all) |
Sequence (Fasta) | MLGTGPAAAT TAATTSSNVS VLQQFASGLK SRNEETRAKA AKELQHYVTM ELREMSQEES 60 TRFYDQLNHH IFELVSSSDA NERKGGILAI ASLIGVEGGN ATRIGRFANY LRNLLPSNDP 120 VVMEMASKAI GRLAMAGDTF TAEYVEFEVK RALEWLGADR NEGRRHAAVL VLRELAISVP 180 TFFFQQVQPF FDNIFVAVWD PKQAIREGAV AALRACLILT TQREPKEMQK PQWYRHTFEE 240 AEKGFDETLA KEKGMNRDDR IHGALLILNE LVRISSMEGE RLREEMEEIT QQQLVHDKYC 300 KDLMGFGTKP RHITPFTSFQ AVQPQQSNAL VGLLGYSSHQ GLMGFGTSPS PAKSTLVESR 360 CCRDLMEEKF DQVCQWVLKC RNSKNSLIQM TILNLLPRLA AFRPSAFTDT QYLQDTMNHV 420 LSCVKKEKER TAAFQALGLL SVAVRSEFKV YLPRVLDIIR AALPPKDFAH KRQKAMQVDA 480 TVFTCISMLA RAMGPGIQQD IKELLEPMLA VGLSPALTAV LYDLSRQIPQ LKKDIQDGLL 540 KMLSLVLMHK PLRHPGMPKG LAHQLASPGL TTLPEASDVG SITLALRTLG SFEFEGHSLT 600 QFVRHCADHF LNSEHKEIRM EAARTCSRLL TPSIHLISGH AHVVSQTAVQ VVADVLSKLL 660 VVGITDPDPD IRYCVLASLD ERFDAHLAQA ENLQALFVAL NDQVFEIREL AICTVGRLSS 720 MNPAFVMPFL RKMLIQILTE LEHSGIGRIK EQSARMLGHL VSNAPRLIRP YMEPILKALI 780 LKLKDPDPDP NPGVINNVLA TIGELAQVSG LEMRKWVDEL FIIIMDMLQD SSLLAKRQVA 840 LWTLGQLVAS TGYVVEPYRK YPTLLEVLLN FLKTEQNQGT RREAIRVLGL LGALDPYKHK 900 VNIGMIDQSR DASAVSLSES KSSQDSSDYS TSEMLVNMGN LPLDEFYPAV SMVALMRIFR 960 DQSLSHHHTM VVQAITFIFK SLGLKCVQFL PQVMPTFLNV IRVCDGAIRE FLFQQLGMLV 1020 SFVKSHIRPY MDEIVTLMRE FWVMNTSIQS TIILLIEQIV VALGGEFKLY LPQLIPHMLR 1080 VFMHDNSPGR IVSIKLLAAI QLFGANLDDY LHLLLPPIVK LFDAPEAPLP SRKAALETVD 1140 RLTESLDFTD YASRIIHPIV RTLDQSPELR STAMDTLSSL VFQLGKKYQI FIPMVNKVLV 1200 RHRINHQRYD VLICRIVKGY TLADEEEDPL IYQHRMLRSG QGDALASGPV ETGPMKKLHV 1260 STINLQKAWG AARRVSKDDW LEWLRRLSLE LLKDSSSPSL RSCWALAQAY NPMARDLFNA 1320 AFVSCWSELN EDQQDELIRS IELALTSQDI AEVTQTLLNL AEFMEHSDKG PLPLRDDNGI 1380 VLLGERAAKC RAYAKALHYK ELEFQKGPTP AILESLISIN NKLQQPEAAA GVLEYAMKHF 1440 GELEIQATWY EKLHEWEDAL VAYDKKMDTN KDDPELMLGR MRCLEALGEW GQLHQQCCEK 1500 WTLVNDETQA KMARMAAAAA WGLGQWDSME EYTCMIPRDT HDGAFYRAVL ALHQDLFSLA 1560 QQCIDKARDL LDAELTAMAG ESYSRAYGAM VSCHMLSELE EVIQYKLVPE RREIIRQIWW 1620 ERLQGCQRIV EDWQKILMVR SLVVSPHEDM RTWLKYASLC GKSGRLALAH KTLVLLLGVD 1680 PSRQLDHPLP TVHPQVTYAY MKNMWKSARK IDAFQHMQHF VQTMQQQAQH AIATEDQQHK 1740 QELHKLMARC FLKLGEWQLN LQGINESTIP KVLQYYSAAT EHDRSWYKAW HAWAVMNFEA 1800 VLHYKHQNQA RDEKKKLRHA SGANITNATT AATTAATATT TASTEGSNSE SEAESTENSP 1860 TPSPLQKKVT EDLSKTLLMY TVPAVQGFFR SISLSRGNNL QDTLRVLTLW FDYGHWPDVN 1920 EALVEGVKAI QIDTWLQVIP QLIARIDTPR PLVGRLIHQL LTDIGRYHPQ ALIYPLTVAS 1980 KSTTTARHNA ANKILKNMCE HSNTLVQQAM MVSEELIRVA ILWHEMWHEG LEEASRLYFG 2040 ERNVKGMFEV LEPLHAMMER GPQTLKETSF NQAYGRDLME AQEWCRKYMK SGNVKDLTQA 2100 WDLYYHVFRR ISKQLPQLTS LELQYVSPKL LMCRDLELAV PGTYDPNQPI IRIQSIAPSL 2160 QVITSKQRPR KLTLMGSNGH EFVFLLKGHE DLRQDERVMQ LFGLVNTLLA NDPTSLRKNL 2220 SIQRYAVIPL STNSGLIGWV PHCDTLHALI RDYREKKKIL LNIEHRIMLR MAPDYDHLTL 2280 MQKVEVFEHA VNNTAGDDLA KLLWLKSPSS EVWFDRRTNY TRSLAVMSMV GYILGLGDRH 2340 PSNLMLDRLS GKILHIDFGD CFEVAMTREK FPEKIPFRLT RMLTNAMEVT GLDGNYRITC 2400 HTVMEVLREH KDSVMAVLEA FVYDPLLNWR LMDTNTKGNK RSRTRTDSYS AGQSVEILDG 2460 VELGEPAHKK TGTTVPESIH SFIGDGLVKP EALNKKAIQI INRVRDKLTG RDFSHDDTLD 2520 VPTQVELLIK QATSHENLCQ CYIGWCPFW |
|
Database | Annotation |
---|---|
Cancer Gene Census | endometrial carcinoma, head and neck, clear cell renal cell carcinoma, anaplastic thyroid cancer, urothelial cell carcinoma, central nervous system tumours, testicular germ cell tumours and other tumour types |
CTD (Curated) (count: 15) (view all) | MESH:D000230
; Adenocarcinoma MESH:D006528 ; Carcinoma, Hepatocellular MESH:D002292 ; Carcinoma, Renal Cell MESH:D018288 ; Carcinoma, Small Cell MESH:C537067 ; Focal cortical dysplasia of Taylor MESH:D006973 ; Hypertension |
DisGeNet (Curated) (count: 19) (view all) | C0001418; Adenocarcinoma
C0007134; Renal Cell Carcinoma C0007873; Uterine Cervical Neoplasm C0020538; Hypertensive disease C0025500; Mesothelioma C0036341; Schizophrenia |
GWASdb (count: 5) | rs12139042; Corneal curvature; corneal disease
rs17036350; Corneal curvature; corneal disease rs2300095; Obesity; obesity rs74225573; Corneal curvature; corneal disease rs12124983; Type 2 diabetes; type 2 diabetes mellitus |
PTM | Modification Sites |
---|---|
Phosphorylation (count: 74) (view all) | 102 GVEGGNATRIGRFAN dbPAF
110 RIGRFANYLRNLLPS dbPAF 1131 APEAPLPSRKAALET dbPAF 1162 IIHPIVRTLDQSPEL dbPAF 1166 IVRTLDQSPELRSTA dbPAF 1171 DQSPELRSTAMDTLS dbPAF |
Acetylation (count: 4) | 1218 VLICRIVKGYTLADE PLMD
1256 PVETGPMKKLHVSTI PLMD 230 REPKEMQKPQWYRHT PLMD 309 DLMGFGTKPRHITPF PLMD |
Ubiquitination (count: 45) (view all) | 1133 EAPLPSRKAALETVD PLMD
1186 SLVFQLGKKYQIFIP PLMD 1187 LVFQLGKKYQIFIPM PLMD 1197 IFIPMVNKVLVRHRI PLMD 1218 VLICRIVKGYTLADE PLMD 1256 PVETGPMKKLHVSTI PLMD |
Malonylation (count: 4) | 1218 VLICRIVKGYTLADE PLMD
2066 ERGPQTLKETSFNQA PLMD 230 REPKEMQKPQWYRHT PLMD 309 DLMGFGTKPRHITPF PLMD |